1. Signaling Pathways
  2. Immunology/Inflammation
  3. Interleukin Related
  4. IL-17 Isoform
  5. IL-17 Antagonist

IL-17 Antagonist

IL-17 Antagonists (4):

Cat. No. Product Name Effect Purity
  • HY-101913
    IL-17A antagonist 1
    Antagonist 99.74%
    IL-17A antagonist 1 (compound 1) is an IL-17A antagonist, with a Kd of 0.66 μM and an IC50 of 1.14 μM.
  • HY-P99280
    Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation.
  • HY-101915
    IL-17A antagonist 3
    Antagonist 98.55%
    IL-17A antagonist 3 is an IL-17A antagonist, compound 3.
  • HY-P3450
    Antagonist 98.60%
    Erepdekinra is an interleukin-17A (IL-17A) receptor antagonist.